CLINICAL TRIALS PROFILE FOR APREMILAST
✉ Email this page to a colleague
All Clinical Trials for APREMILAST
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00456092 ↗ | Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis | Completed | Amgen | Phase 2 | 2007-03-05 | This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis. |
NCT00456092 ↗ | Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis | Completed | Celgene Corporation | Phase 2 | 2007-03-05 | This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis. |
NCT00521339 ↗ | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | Completed | Amgen | Phase 2 | 2007-08-01 | The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis. |
NCT00521339 ↗ | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | Completed | Celgene Corporation | Phase 2 | 2007-08-01 | The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis. |
NCT00604682 ↗ | Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis | Completed | Amgen | Phase 2 | 2005-01-01 | Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis. |
NCT00604682 ↗ | Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis | Completed | Celgene Corporation | Phase 2 | 2005-01-01 | Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis. |
NCT00606450 ↗ | Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis | Completed | Amgen | Phase 2 | 2006-04-01 | There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study. The information obtained from the study will aid in the design of future clinical trials and to establish the safety and efficacy of CC-10004. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for APREMILAST
Condition Name
Clinical Trial Locations for APREMILAST
Trials by Country
Clinical Trial Progress for APREMILAST
Clinical Trial Phase
Clinical Trial Sponsors for APREMILAST
Sponsor Name